We report a 7-year-old girl with hemophagocytic lymphohistiocytosis who received a syngeneic bone marrow transplant from her twin sister. 
Hemophagocytic lymphohistiocytosis (HLH) is a rare lifethreatening disorder presenting with high fever, hepatosplenomegaly, pancytopenia, liver dysfunction, hypertriglyceridemia, and hemophagocytosis in the bone marrow, spleen, or lymph nodes. HLH has been classified into primary and secondary types. Primary HLH, also known as familial hemophagocytic lymphohistiocytosis (FHL), exhibits an autosomal-recessive mode of inheritance. Secondary HLH is more often associated with infections, immune disorders, or malignancy. The management of HLH is sometimes quite difficult, and some patients are resistant to chemotherapy and have a fatal course. Allogeneic bone marrow transplantation from HLA-identical related or unrelated donors has been considered the treatment of choice for those patients. 1, 2 The presence of an underlying defect in immunological defense against EBV has been speculated Correspondence: Dr K Sano, Department of Pediatrics, Kobe University School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017 Japan Received 16 November 1998; accepted 22 March 1999 to be present in EBV-associated HLH cases. It is not known whether or not syngeneic BMT is curative in these cases.
We describe here for the first time an EB virus-associated HLH patient who was resistant to chemotherapy, but obtained prolonged remission after syngeneic bone marrow transplantation following high-dose combination chemotherapy.
Case report
A 7-year-old girl was admitted to our hospital because of a 2-week history of fever and cough. There was no past history of illness including in the perinatal period. She is one of two HLA-identical twins born from healthy nonconsanguineous parents. There was no family history of HLH or immunological disorders. She was observed in a neighboring hospital, where she underwent administration of rhG-CSF and platelet transfusions from 1 to 4 March 1997, but developed pancytopenia, and was referred to our institution on 4 March 1997.
On admission to our hospital, she had a fever of 38.5°C. She was pale, and petechiae were present on her trunk and extremities. Cervical lymph nodes were not palpable. The tip of the liver was palpable below the costal margin, but the spleen was not palpable. There were no meningeal signs. Peripheral blood count revealed a WBC of 1.7 ϫ 10 6 /l with 23% band forms, 46% segmented neutrophils, 30% lymphocytes, and 1% monocytes, RBC 336 ϫ 10 9 /l, hemoglobin 9.4 g/dl, and a platelet count of 3.1 ϫ 10 9 /l. Blood chemistry results were as follows: aspartate aminotransferase, 165 IU/l; alanine aminotransferase, 105 IU/l; lactate dehydrogenase, 2052 IU/l; triglyceride, 139 mg/dl; and total bilirubin, 0.5 mg/dl with 0.1 mg/dl of direct bilirubin. Serum ferritin was elevated to 5000 ng/ml. C-reactive protein was increased to 2.68 mg/dl. Serum immunoglobulin levels were IgG, 997 mg/dl; IgA, 130 mg/dl; and IgM, 138 mg/dl. Fibrinogen was 208 mg/dl. Results of serological examinations suggested a primary infection with EBV. On admission, the titers against EBV were VCA IgG, ϫ 320; VCA IgM, Ͻϫ 10, and EBNA, Ͻϫ 10. Two months later, they were VCA IgG, ϫ 640; VCA IgM, Ͻϫ 10, and EBNA, ϫ 10. EB viral genome was detected in mononuclear cells by polymerase chain reaction. Bone marrow examination revealed hypocellularity of all cell lineages. Some histiocytic hemophagocytes and an increase of cells with blastic features were observed on the bone marrow smear. Central nervous system involvement by histiocytic hemophagocytosis was not observed. Southern blot analysis of the bone marrow cells using an EBV terminal probe revealed a monoclonal proliferation of EBV-infected lymphocytes. Soluble serum/IL-2 receptor was elevated to 21 415 U/ml (normal range; 190-650 U/ml). Serum level of neopterin, a marker for high serum levels of interferon-␥, was elevated to 312 nmol/l (normal range; 10.6-25.9 nmol/l). On the basis of the patient's clinical presentation, a presumptive diagnosis of HLH was made. Furthermore, we presumed that our patient had EBV-associated peripheral T cell lymphoma with hemophagocytic features (EBV-PTCL), based on the results of the laboratory tests for the EBV genome and clonality.
Conventional treatment including prednisolone (PSL, 2 mg/kg/day) and ␥-globulin (100 mg/kg/day) was started early in the clinical course. These treatments yielded only transient defervescence. She subsequently became resistant to these treatments, as shown in Figure 1 . Therefore, a regimen of etoposide, weekly at 300 mg/m 2 , dexamethasone, daily at 10 mg/m 2 for 2 weeks, and cyclosporin A, daily at 3 mg/kg, was started in accordance with the HLH94-protocol. 3 This treatment did not ameliorate disease activity. Finally, she developed severe pancytopenia 3 weeks after referral to our institution. Daily administration of rhG-CSF (100 g/m 2 ) did not increase her peripheral blood white cell count above 0.1 ϫ 10 6 /l. Rapid decrease in platelets necessitated daily platelet transfusions. We therefore planned a syngeneic transplant from her HLA-identical twin sister. Genetic identity between the patient and her sister was confirmed by DNA fingerprinting. 
Discussion
HLH is considered a cytokine disease, and is detected by hypercytokinemia in serum and plasma. Uncontrolled secretion of various cytokines such as IFN-␥, TNF-␣, IL-6, and soluble Fas ligand by either benign or neoplastic T cells is believed to be responsible for a variety of symptoms observed in HLH. Previous reports have suggested that abnormalities in the immune regulatory system play a central role in secondary as well as primary HLH. 4 Etoposide and cyclosporin A are the most effective drugs for HLH. However, some patients with secondary HLH exhibit deterioration without any response to supportive therapy or chemotherapy, as did the present case.
Allogeneic BMT from HLA-identical related or unrelated donors has been performed for HLH patients. Arico et al 1 analyzed results for 122 patients with HLH registered in an international study, and found that the estimated 5-year survival rate was 10.1% for patients with HLH treated with chemotherapy alone, but 66% for those undergoing allogeneic BMT. Allogenic BMT is thus an option in the treatment of patients with HLH who are likely to have a poor prognosis. However, it remains unclear which patients with secondary HLH should receive BMT. Ohga et al 5 recently described the first successful autologous peripheral blood stem cell transplant in a 30-month-old boy with HLH. Autologous stem cell transplantation might therefore be considered for patients with secondary HLH in cases in which autologous stem cells can be collected. Our patient underwent syngeneic bone marrow transplantation from a genetically identical twin sister. To our knowledge, this is the first case reported in the literature in which syngeneic BMT was successfully performed for a patient with secondary HLH. It has been speculated that lack of cellular immunity, including lack of NK cell activities, is involved in the vulnerability to EBV in some case of HLH. 6 However, there is at present no direct evidence that sporadic EBV-related HLH patients have a genetic predisposition to impaired immunological reaction against EBV. If these patients have a genetic defect, identical twins might have the same immunological defect and syngeneic BMT might not be curative in EBV-related HLH. However, the clinical course of our patient suggests that syngeneic BMT might be curative for EBV-related HLH. We hypothesize that myeloablative therapy followed by stem cell infusion resets the abnormally activated immunological states present in secondary HLH, leading to resolution of the disease. These findings suggest that autologous PBSCT or syngeneic BMT may be considered for secondary HLH patients, since they are less toxic than is allogeneic BMT.
